| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 9.66M | 11.01M | 51.76M | 53.02M | 29.54M | 38.95M | 26.68M | 412.48M | 76.01M | 76.3M |
| Revenue Growth % | 4.78% | 0.14% | 3.7% | 0.02% | -0.44% | 0.32% | -0.32% | 14.46% | -0.82% | 0% |
| Cost of Goods Sold | 24.4M | 35.55M | 41.14M | 56.93M | 117.1M | 170.9M | 0 | 0 | 142.99M | 0 |
| COGS % of Revenue | 2.53% | 3.23% | 0.79% | 1.07% | 3.96% | 4.39% | - | - | 1.88% | - |
| Gross Profit | -14.74M | -24.54M | 10.62M | -3.91M | -87.55M | -131.94M | 26.68M | 412.48M | -66.98M | 76.3M |
| Gross Margin % | -1.53% | -2.23% | 0.21% | -0.07% | -2.96% | -3.39% | 1% | 1% | -0.88% | 1% |
| Gross Profit Growth % | -0.67% | -0.66% | 1.43% | -1.37% | -21.41% | -0.51% | 1.2% | 14.46% | -1.16% | 2.14% |
| Operating Expenses | 29.62M | 48.1M | 59.22M | 86.15M | 63.75M | 55.52M | 242.31M | 281.95M | 71.08M | 213.41M |
| OpEx % of Revenue | 3.07% | 4.37% | 1.14% | 1.62% | 2.16% | 1.43% | 9.08% | 0.68% | 0.94% | 2.8% |
| Selling, General & Admin | 5.22M | 12.55M | 18.55M | 29.46M | 62.88M | 55.17M | 42.6M | 73.4M | 70.4M | 61.5M |
| SG&A % of Revenue | 0.54% | 1.14% | 0.36% | 0.56% | 2.13% | 1.42% | 1.6% | 0.18% | 0.93% | 0.81% |
| Research & Development | 24.65M | 36.82M | 41.75M | 56.68M | 118.25M | 171.34M | 199.75M | 208.6M | 143.62M | 134.62M |
| R&D % of Revenue | 2.55% | 3.34% | 0.81% | 1.07% | 4% | 4.4% | 7.49% | 0.51% | 1.89% | 1.76% |
| Other Operating Expenses | -251K | -1.26M | -964K | -1.26M | -117.37M | -171M | -39K | -42K | -142.94M | 17.29M |
| Operating Income | -19.96M | -37.86M | -9M | -33.13M | -151.3M | -187.47M | -215.63M | 130.53M | -138.05M | -137.11M |
| Operating Margin % | -2.07% | -3.44% | -0.17% | -0.62% | -5.12% | -4.81% | -8.08% | 0.32% | -1.82% | -1.8% |
| Operating Income Growth % | -0.57% | -0.9% | 0.76% | -2.68% | -3.57% | -0.24% | -0.15% | 1.61% | -2.06% | 0.01% |
| EBITDA | -19.47M | -36.84M | -6.26M | -29.5M | -148.99M | -184.11M | -206.05M | 142.53M | -120.75M | -125.92M |
| EBITDA Margin % | -2.02% | -3.35% | -0.12% | -0.56% | -5.04% | -4.73% | -7.72% | 0.35% | -1.59% | -1.65% |
| EBITDA Growth % | -0.58% | -0.89% | 0.83% | -3.71% | -4.05% | -0.24% | -0.12% | 1.69% | -1.85% | -0.04% |
| D&A (Non-Cash Add-back) | 494K | 1.02M | 2.74M | 3.63M | 2.31M | 3.35M | 9.58M | 12M | 17.3M | 11.19M |
| EBIT | -19.12M | -37.93M | -7.93M | -33.36M | -150.43M | -187.12M | -215.67M | 130.49M | -138.01M | -119.82M |
| Net Interest Income | 306K | -642K | -397K | 2.47M | 5.88M | 5.7M | 1.97M | 3.6M | 19.7M | 19.94M |
| Interest Income | 324K | 308K | 743K | 2.64M | 5.88M | 5.7M | 1.97M | 3.6M | 19.7M | 19.94M |
| Interest Expense | 18K | 950K | 1.14M | 166K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 824K | -1.02M | -964K | -1.02M | 6.45M | 7.34M | 3.27M | 4.71M | 18.81M | 20.5M |
| Pretax Income | -19.14M | -38.88M | -9.96M | -34.38M | -144.85M | -180.12M | -212.36M | 135.23M | -119.24M | -116.61M |
| Pretax Margin % | -1.98% | -3.53% | -0.19% | -0.65% | -4.9% | -4.62% | -7.96% | 0.33% | -1.57% | -1.53% |
| Income Tax | 34K | -5.08M | 444K | 2.17M | 582K | 429K | -516K | 10.89M | -568K | 6.08M |
| Effective Tax Rate % | 1% | 0.87% | 1.04% | 1.06% | 1% | 1% | 1% | 0.92% | 1% | 1.05% |
| Net Income | -19.17M | -33.81M | -10.41M | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.69M |
| Net Margin % | -1.98% | -3.07% | -0.2% | -0.69% | -4.92% | -4.64% | -7.94% | 0.3% | -1.56% | -1.61% |
| Net Income Growth % | -0.48% | -0.76% | 0.69% | -2.51% | -2.98% | -0.24% | -0.17% | 1.59% | -1.95% | -0.03% |
| Net Income (Continuing) | -19.17M | -33.81M | -10.41M | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.69M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.97 | -1.72 | -0.49 | -1.26 | -3.83 | -3.58 | -4.06 | 1.90 | -1.72 | -1.62 |
| EPS Growth % | -0.49% | -0.77% | 0.72% | -1.57% | -2.04% | 0.07% | -0.13% | 1.47% | -1.91% | 0.06% |
| EPS (Basic) | -0.97 | -1.72 | -0.49 | -1.26 | -3.83 | -3.58 | -4.06 | 1.91 | -1.72 | -1.62 |
| Diluted Shares Outstanding | 19.84M | 19.7M | 21.32M | 29.09M | 38.02M | 50.38M | 52.13M | 65.25M | 68.86M | 75.88M |
| Basic Shares Outstanding | 19.84M | 19.7M | 21.25M | 29.01M | 37.97M | 50.38M | 52.13M | 65.19M | 68.86M | 75.85M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17.68M | 46.48M | 92.33M | 204.37M | 311.83M | 455.08M | 288.22M | 544.71M | 412.93M | 300.45M |
| Cash & Short-Term Investments | 15.16M | 40.26M | 87.8M | 200.16M | 298.9M | 426.35M | 252.61M | 492.23M | 374.33M | 225.78M |
| Cash Only | 11.52M | 16.44M | 35.95M | 42.2M | 128.45M | 242.04M | 201.87M | 400.91M | 157.56M | 66.1M |
| Short-Term Investments | 3.64M | 23.82M | 51.85M | 157.96M | 170.45M | 184.32M | 50.74M | 91.32M | 216.77M | 159.67M |
| Accounts Receivable | 2.27M | 4.31M | 2.33M | 358K | 2.19M | 15.29M | 15.61M | 33.4M | 19.48M | 55.81M |
| Days Sales Outstanding | 85.58 | 142.8 | 16.43 | 2.46 | 26.99 | 143.31 | 213.61 | 29.56 | 93.53 | 266.99 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.07M | 19.12M | 18.86M |
| Total Non-Current Assets | 5.47M | 47.51M | 39.62M | 39.99M | 56.38M | 83.3M | 100.91M | 104.02M | 167.95M | 162.64M |
| Property, Plant & Equipment | 781K | 6.72M | 7.18M | 6.48M | 16.5M | 17.61M | 49.77M | 47.65M | 37.54M | 34.32M |
| Fixed Asset Turnover | 12.37x | 1.64x | 7.21x | 8.18x | 1.79x | 2.21x | 0.54x | 8.66x | 2.02x | 2.22x |
| Goodwill | 0 | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M | 12.02M |
| Intangible Assets | 144K | 20.63M | 19.14M | 20.01M | 23.68M | 22.93M | 21.47M | 26.38M | 25.28M | 4.58M |
| Long-Term Investments | 4.18M | 0 | 0 | 0 | 0 | 25.92M | 886K | 886K | 81.93M | 98.43M |
| Other Non-Current Assets | 360K | 3.04M | 1.22M | 1.4M | 2.96M | 3.1M | 13.7M | 15.74M | 7.57M | 8.92M |
| Total Assets | 23.15M | 94M | 131.96M | 244.36M | 368.2M | 538.38M | 389.13M | 648.73M | 580.88M | 463.09M |
| Asset Turnover | 0.42x | 0.12x | 0.39x | 0.22x | 0.08x | 0.07x | 0.07x | 0.64x | 0.13x | 0.16x |
| Asset Growth % | -0.54% | 3.06% | 0.4% | 0.85% | 0.51% | 0.46% | -0.28% | 0.67% | -0.1% | -0.2% |
| Total Current Liabilities | 4.85M | 16.56M | 14.66M | 29.99M | 82.55M | 85.67M | 71.85M | 95.63M | 55.76M | 88.29M |
| Accounts Payable | 2.11M | 2.96M | 1.66M | 2.6M | 5.35M | 6.24M | 5.17M | 7.86M | 6.21M | 3.9M |
| Days Payables Outstanding | 31.59 | 30.34 | 14.76 | 16.66 | 16.67 | 13.34 | - | - | 15.86 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 0 | 0 | 0 | 1000K | 1000K | 1000K |
| Other Current Liabilities | 48K | 5.69M | 2.04M | 20.63M | 50.59M | 48.74M | 11.1M | 16.01M | 8.68M | 7.49M |
| Current Ratio | 3.64x | 2.81x | 6.30x | 6.82x | 3.78x | 5.31x | 4.01x | 5.70x | 7.41x | 3.40x |
| Quick Ratio | 3.64x | 2.81x | 6.30x | 6.82x | 3.78x | 5.31x | 4.01x | 5.70x | 7.41x | 3.40x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 59K | 68.44M | 866K | 33.89M | 39.97M | 42.79M | 68.19M | 60.14M | 60.31M | 36.03M |
| Long-Term Debt | 0 | 4.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 49K | 52K | 42K | 5.64M | 5.93M | 31.02M | 24.79M | 22.46M | 15.77M |
| Deferred Tax Liabilities | 16K | 5.02M | 0 | 114K | 408K | 1.18M | 1.57M | 1.79M | 3.3M | 4.76M |
| Other Non-Current Liabilities | 43K | 58.95M | 814K | 904K | 978K | 2.73M | 2.65M | 2.98M | 1.61M | 895K |
| Total Liabilities | 4.91M | 84.99M | 15.53M | 63.87M | 122.52M | 128.45M | 140.04M | 155.77M | 116.07M | 124.32M |
| Total Debt | 6K | 4.42M | 62K | 57K | 6.93M | 8.64M | 32.33M | 28.11M | 26.72M | 18.51M |
| Net Debt | -11.51M | -12.01M | -35.88M | -42.15M | -121.52M | -233.39M | -169.53M | -372.8M | -130.84M | -47.6M |
| Debt / Equity | 0.00x | 0.49x | 0.00x | - | 0.03x | 0.02x | 0.13x | 0.06x | 0.06x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | 0.20x | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | -2.62x | - | - |
| Interest Coverage | -1108.89x | -39.86x | -7.89x | -199.56x | - | - | - | - | - | - |
| Total Equity | 18.24M | 9M | 116.43M | -145.27M | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M | 338.77M |
| Equity Growth % | -0.54% | -0.51% | 11.93% | -2.25% | 2.69% | 0.67% | -0.39% | 0.98% | -0.06% | -0.27% |
| Book Value per Share | 0.92 | 0.46 | 5.46 | -4.99 | 6.46 | 8.14 | 4.78 | 7.55 | 6.75 | 4.46 |
| Total Shareholders' Equity | 18.24M | 9M | 116.43M | -145.27M | 245.68M | 409.92M | 249.09M | 492.96M | 464.81M | 338.77M |
| Common Stock | 83.61M | 106.59M | 222.99M | 320.07M | 450.21M | 724.22M | 741.15M | 906.76M | 1.01B | 1.02B |
| Retained Earnings | -63.92M | -97.79M | -108.72M | -145.27M | -290.71M | -471.26M | -683.1M | -558.76M | -677.44M | -830.34M |
| Treasury Stock | 0 | -6.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.66M | -6.6M | -6.95M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -22.17M | -35.25M | 219K | 24.18M | -81.85M | -151.4M | -192.45M | 144.11M | -118.3M | -110.04M |
| Operating CF Margin % | -2.3% | -3.2% | 0% | 0.46% | -2.77% | -3.89% | -7.21% | 0.35% | -1.56% | -1.44% |
| Operating CF Growth % | -2.16% | -0.59% | 1.01% | 109.4% | -4.39% | -0.85% | -0.27% | 1.75% | -1.82% | 0.07% |
| Net Income | -19.17M | -33.81M | -10.41M | -36.56M | -145.44M | -180.55M | -211.84M | 124.34M | -118.67M | -122.69M |
| Depreciation & Amortization | 494K | 1.02M | 2.74M | 3.63M | 7.33M | 10.28M | 9.58M | 12M | 17.3M | 11.19M |
| Stock-Based Compensation | 1.39M | 4.29M | 3.43M | 13.44M | 49M | 29.12M | 10.76M | 4.01M | 8.1M | 17.79M |
| Deferred Taxes | 16K | -5.5M | 15K | -17K | -726K | 266K | -953K | 1.94M | -757K | 691K |
| Other Non-Cash Items | -5.06M | 1.12M | 2.66M | 3.75M | 1.54M | -364K | -387K | -2.21M | 1.27M | 13.93M |
| Working Capital Changes | -4.9M | -2.37M | 1.78M | 39.92M | 6.44M | -10.15M | 393K | 4.01M | -25.55M | -30.95M |
| Change in Receivables | -1.36M | -592K | 2.41M | -119K | -1.83M | -13.11M | -266K | -17.51M | 13.92M | -36.36M |
| Change in Inventory | 1.56M | 0 | 0 | -111K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.42M | 1.93M | -358K | 3.68M | 21.57M | 7.62M | 16.48M | 26.48M | -44.77M | 14.34M |
| Cash from Investing | -9.2M | -25.45M | -30.89M | -109.05M | -25.59M | -43.44M | 144.6M | -53.85M | -207.25M | 38.76M |
| Capital Expenditures | -853K | -5.46M | -3.12M | -3.42M | -6.32M | -6.26M | -12.4M | -13.13M | -2.47M | -1.99M |
| CapEx % of Revenue | 0.09% | 0.5% | 0.06% | 0.06% | 0.21% | 0.16% | 0.46% | 0.03% | 0.03% | 0.03% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -4.31M | -19.99M | -27.77M | -105.63M | -7.56M | -1.96M | -881K | 40.72M | -1.6M | -1.07M |
| Cash from Financing | 1.52M | 64.78M | 49.95M | 91.43M | 193.66M | 308.98M | 8.01M | 108.58M | 81.85M | -20.45M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -232K | -1.03M | 1.98M | 690K | 5.45M | 8.11M | 8.03M | 1.06M | 5.77M | 9.61M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -23.02M | -40.71M | -2.9M | 20.76M | -95.73M | -157.67M | -205.74M | 130.98M | -122.38M | -113.11M |
| FCF Margin % | -2.38% | -3.7% | -0.06% | 0.39% | -3.24% | -4.05% | -7.71% | 0.32% | -1.61% | -1.48% |
| FCF Growth % | -2.16% | -0.77% | 0.93% | 8.15% | -5.61% | -0.65% | -0.3% | 1.64% | -1.93% | 0.08% |
| FCF per Share | -1.16 | -2.07 | -0.14 | 0.71 | -2.52 | -3.13 | -3.95 | 2.01 | -1.78 | -1.49 |
| FCF Conversion (FCF/Net Income) | 1.16x | 1.04x | -0.02x | -0.66x | 0.56x | 0.84x | 0.91x | 1.16x | 1.00x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.18M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -66.1% | -248.22% | -16.59% | - | -289.69% | -55.08% | -64.29% | 33.51% | -24.78% | -30.54% |
| Return on Invested Capital (ROIC) | -222.57% | -1528.42% | -17.41% | - | -91.4% | -93.52% | -126.3% | 98.03% | -45.6% | -32.9% |
| Gross Margin | -152.62% | -222.93% | 20.51% | -7.37% | -296.34% | -338.75% | 100% | 100% | -88.11% | 100% |
| Net Margin | -198.45% | -307.1% | -20.1% | -68.95% | -492.27% | -463.54% | -794.01% | 30.14% | -156.13% | -160.8% |
| Debt / Equity | 0.00x | 0.49x | 0.00x | - | 0.03x | 0.02x | 0.13x | 0.06x | 0.06x | 0.05x |
| Interest Coverage | -1108.89x | -39.86x | -7.89x | -199.56x | - | - | - | - | - | - |
| FCF Conversion | 1.16x | 1.04x | -0.02x | -0.66x | 0.56x | 0.84x | 0.91x | 1.16x | 1.00x | 0.90x |
| Revenue Growth | 478.44% | 13.96% | 370.18% | 2.43% | -44.28% | 31.84% | -31.5% | 1446.03% | -81.57% | 0.38% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Milestone Revenue | - | - | - | - | - | - | 25M |
| Milestone Revenue Growth | - | - | - | - | - | - | - |
| Research Support Payments And Other Service | - | 4.01M | 7.95M | 5.68M | 8.2M | 52.62M | 2.83M |
| Research Support Payments And Other Service Growth | - | - | 98.08% | -28.56% | 44.38% | 541.62% | -94.61% |
| Royalty | - | - | - | - | - | - | 100K |
| Royalty Growth | - | - | - | - | - | - | - |
| Licensing Fee | - | - | - | - | 5M | - | - |
| Licensing Fee Growth | - | - | - | - | - | - | - |
| Performance Milestone | 2M | 2M | 15M | 8M | - | - | - |
| Performance Milestone Growth | - | 0.00% | 650.00% | -46.67% | - | - | - |
| Partner Revenue | - | - | 4M | - | - | - | - |
| Partner Revenue Growth | - | - | - | - | - | - | - |
| Option Exercise Fee | - | 7.5M | - | - | - | - | - |
| Option Exercise Fee Growth | - | - | - | - | - | - | - |
| Commercial License Option Exercise | - | 3.5M | - | - | - | - | - |
| Commercial License Option Exercise Growth | - | - | - | - | - | - | - |
| License | 4M | - | - | - | - | - | - |
| License Growth | - | - | - | - | - | - | - |
| Service, Other | 373K | - | - | - | - | - | - |
| Service, Other Growth | - | - | - | - | - | - | - |
Zymeworks Inc. (ZYME) reported $134.5M in revenue for fiscal year 2024. This represents a 7953% increase from $1.7M in 2014.
Zymeworks Inc. (ZYME) grew revenue by 0.4% over the past year. Growth has been modest.
Zymeworks Inc. (ZYME) reported a net loss of $63.4M for fiscal year 2024.
Zymeworks Inc. (ZYME) has a return on equity (ROE) of -30.5%. Negative ROE indicates the company is unprofitable.
Zymeworks Inc. (ZYME) had negative free cash flow of $66.2M in fiscal year 2024, likely due to heavy capital investments.